We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Moscow’s Gamaleya Institute, the developer of the first Russian vaccine against COVID-19, said on Wednesday that volunteers in its large-scale final-stage trials for the Sputnik V shot will no longer receive placebos, RIA news agency reported.